Taiwan · Delayed Price · Currency is TWD Lumosa Therapeutics Company Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe.
The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery.
It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology.
In addition, the company engages in the investment, consulting, service, and transfer of techniques activities.
Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Sheng Wen Yeh |
Contact Details
Address: No. 3-2, Park Street Taipei, 11503 Taiwan | |
| Phone | 886 2 2655 7918 |
| Website | lumosa.com.tw |
Stock Details
| Ticker Symbol | 6535 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006535008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sheng Wen Yeh | General Manager |
| Li Fang Pan | Chief Financial Officer and Manager of the Administrative Office |
| Pei-Jiun Chen | Chief Operating Officer |